AMED250117C70000
- 0.00
- 0.000.00%
Amedisys Newsroom
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neurocrine (NBIX) and Amedisys (AMED)
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
UnitedHealth's Effort to Buy Another Home Health Provider at Risk Amid DOJ Lawsuit
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys Analyst Ratings
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Deutsche Bank Downgrades Amedisys to Hold From Buy, Price Target Is $101
TD Cowen Initiates Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Amedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition Offer
Amedisys Price Target Maintained With a $101.00/Share by Cantor Fitzgerald
Amedisys Analyst Ratings
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys (AMED) Gets a Hold From TD Cowen
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Amedisys (AMED) and Draegerwerk AG & Co. KGaA (GB:0K5E)
Jefferies Upgrades UnitedHealth to Buy, Cites Growth Outlook